Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06888193 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
A Phase 1 study of Hidradenitis Suppurativa and Psoriatic Arthritis, sponsored by UCB Biopharma SRL.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 10
- Study locations
NCT06888193 is a Phase 1 study of Hidradenitis Suppurativa and Psoriatic Arthritis that is actively recruiting participants, run by UCB Biopharma SRL. The registered enrollment target is 20 participants, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (97% lower). The trial reports 10 study locations across 4 states.
The verdict
NCT06888193, a Phase 1 study of Hidradenitis Suppurativa and Psoriatic Arthritis, is actively recruiting participants, sponsored by UCB Biopharma SRL.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 10
- Study locations
Study Summary
Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.
Conditions Studied
Interventions
- DRUG Bimekizumab
Study Locations (10)
Other
- Up0122 202 - Calgary
- Up0122 201 - Vancouver
- Up0122 303 - Herne
- Up0122 501 - Barcelona
- Up0122 502 - Barcelona
- Up0122 602 - Lausanne
- Up0122 601 - Sankt Gallen
California
- Up0122 105 - Santa Monica
Florida
- Up0122 103 - South Miami
North Carolina
- Up0122 102 - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-11-05 |
| Est. Completion | 2027-05-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06888193
The ClinicalTrials.gov registry entry for NCT06888193 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (97% lower). The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention - of which Bimekizumab is the first listed.
NCT06888193 reports 10 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06888193 about?
NCT06888193 is a clinical study titled "A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)". Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.
What is the current status of trial NCT06888193?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-11-05. Estimated completion is 2027-05-03.
What conditions does trial NCT06888193 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa, Psoriatic Arthritis, Axial Spondyloarthritis, Moderate to Severe Plaque Psoriasis.
What interventions are being tested in trial NCT06888193?
The interventions under investigation include: Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT06888193?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06888193 being conducted?
This trial has 10 study locations across California, Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
RECRUITING · Phase 1
-
Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa
ACTIVE NOT RECRUITING · Phase 1
-
Aviclear for Hidradenitis Suppurativa (HS)
RECRUITING · NA
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.